自噬抑制剂在免疫介导炎症性疾病中阻断致病性NET释放而不损害宿主防御
研究从健康对照及类风湿关节炎(RA)、系统性红斑狼疮(SLE)患者分离中性粒细胞,用超过220种小分子激酶抑制剂筛选能抑制NET产生和活性氧(ROS)而不影响中性粒细胞凋亡或杀灭金黄色葡萄球菌的化合物。发现50种化合物抑制NOX2依赖和非依赖的NET产生,其中7种不显著损害ROS产生或凋亡;仅ULK1、JNK和ROCK1/2抑制剂不显著损害杀菌。作者提出自噬信号通路是阻断NET释放的新靶点。
要点
- 50种化合物抑制NOX2依赖和非依赖的NET产生(P < 0.05,n = 5 HC、RA和SLE)。
- 7种化合物不显著损害ROS产生或凋亡,其靶点涉及自噬、细胞周期检查点和EGFR酪氨酸激酶信号。
- 仅ULK1、JNK和ROCK1/2抑制剂不显著损害杀菌(n = 5 HC,P > 0.05),且自噬抑制剂抑制免疫复合物驱动的NET产生。
核心结论
- 作者提出自噬信号通路是开发小分子治疗以阻断免疫介导炎症性疾病中不必要的中性粒细胞活化和NET释放的新靶点。
研究设计与样本
- 研究从健康对照(HC)及RA或SLE患者分离中性粒细胞,用超过220种小分子激酶抑制剂(KCGS)筛选抑制NET产生和ROS产生而不损害中性粒细胞凋亡或杀灭金黄色葡萄球菌的能力。
主要发现
- 50种化合物(名义靶向29种蛋白激酶)抑制NOX2依赖(PMA刺激)和NOX2非依赖(A23187刺激)的NET产生(P < 0.05,n = 5 HC、RA和SLE)。
- 7种化合物不显著损害ROS产生或凋亡,其去卷积靶点涉及自噬、细胞周期检查点和表皮生长因子酪氨酸激酶信号三条通路。
- 仅ULK1、JNK和ROCK1/2抑制剂不显著损害杀菌(n = 5 HC,P > 0.05),且自噬抑制剂抑制免疫复合物驱动的NET产生(P < 0.05,n = 5 HC、RA和SLE)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Activation of neutrophils and release of neutrophil extracellular traps (NETs), proteases and reactive oxygen species (ROS) is pathogenic in immune-mediated inflammatory diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), driving inflammation and damaging host tissues. The aim of this research was to identify small molecule inhibitors of NET production using a highly curated panel of narrow-spectrum small molecule kinase inhibitors termed the kinase chemogenomic set (KCGS). METHODS: Neutrophils were isolated from healthy controls (HC) and people with RA or SLE. Over 220 small molecules were screened for their ability to inhibit NET production and decrease ROS production without impairing neutrophil apoptosis or killing of Staphylococcus aureus bacteria. RESULTS: Fifty compounds, nominally targeting 29 individual protein kinases, were found to inhibit NADPH oxidase 2 (NOX2) -dependent (phorbol 12-myristate 13-acetate-stimulated) and NOX2-independent (A23187-stimulated) NET production (P < 0.05, n = 5 HC, RA and SLE). Of these, seven compounds did not significantly impair ROS production or apoptosis. The deconvoluted targets of these small molecules inhibit kinases that operate in three cellular pathways: autophagy, cell cycle checkpoint and epidermal growth factor tyrosine kinase signalling. Of these, only inhibitors of ULK1, JNK and ROCK1/2, broadly implicated in the regulation of autophagy, did not significantly impair bacterial killing (n = 5 HC, P > 0.05). Autophagy inhibitors were also able to inhibit immune-complex driven NET production (P < 0.05, n = 5 HC, RA and SLE). CONCLUSION: We propose that autophagy signalling pathways represent novel and exciting targets for the development of small molecule therapeutics to block unwanted neutrophil activation and NET release in immune-mediated inflammatory disease.
引用
- Nolan A, Foulkes DM, Fairweather EE, et al. Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. Rheumatology (Oxford). 2025. PMID: 40802538. doi:10.1093/rheumatology/keaf437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。